Pre-seed investing finances a company before much of the evidence a later investor would expect exists. The strategy works as a process when the investor specifies which uncertainty the first cheque should help resolve.
Without that discipline, a portfolio can become a collection of appealing founders funded on unrelated assumptions. A repeatable approach does not require identical companies. It requires decisions that can be compared and improved.
Define the stage through evidence
Round labels are imprecise. One company's pre-seed round funds a prototype; another's funds commercial testing of a working product.
Define your investable stage in operational terms. For example: a team has demonstrated a technical capability and identified potential buyers, but has not established a repeatable paid deployment. State the evidence you require and the uncertainty you are prepared to fund.
That definition helps screen opportunities and keeps the portfolio coherent. It also prevents a fashionable round label from concealing a much later valuation or a much earlier technical risk.
Underwrite the next useful test
For each opportunity, write the question the proposed financing should answer. “Grow revenue” is usually too vague. “Show that three unrelated customers will pay for and use the product without founder-led custom development” creates a more useful test.
Build the cost and timing of that test into the financing plan. Include hiring delays, one-off equipment, working capital and a buffer for a slower result.
An illustrative company raising £600,000 might budget £60,000 for setup and £60,000 as a cash buffer, leaving £480,000 for operating burn. At £40,000 a month, that supports 12 months of planned activity. If the decisive evidence takes 15 months, the financing and milestone are misaligned before the investment begins.
The milestone should matter to the business, not merely make the next fundraising deck look stronger.
Set a sourcing cadence the team can sustain
Build access around the evidence you can evaluate: a technical community, an industry problem or a repeatable founder profile supported by relevant work.
Track opportunities through defined stages: received, within mandate, first meeting, detailed review and decision. Review the reasons for passing. A high volume of pitches outside the mandate suggests a sourcing problem, not necessarily a need to broaden the strategy.
Set aside time for existing investments before filling the calendar with new meetings. At this stage, a product or founder-role change may require more attention than the original plan anticipated.
Use a consistent investment record
The memo should capture the same core information across companies:
- What has been demonstrated and what remains a hypothesis.
- The next milestone, its cost and the expected timing.
- The offered security, price and plausible ownership after dilution.
- The next financing requirement and who might fund it.
- The strongest reason to decline.
Consistency makes later comparison possible. It does not mean assigning spurious numerical precision to uncertain founder or market judgements.
For the ownership mechanics behind the cheque, see our guide to what an early-stage investment buys.
Make follow-on gates explicit
Distinguish a milestone being reached from a new round being attractive. A company may improve substantially while its price rises even faster.
Before committing more, reassess the evidence, security, financing plan and concentration of your exposure. Record why the new investment is preferable to other uses of the capital. The original investment's survival is not the only objective.
Avoid promising support the strategy cannot fund. If follow-on participation depends on a separate raise, describe it as conditional. A founder should understand the difference between reserved fund capital and the possibility of future investor interest.
Review cohorts before the exits arrive
Group investments by decision period and initial evidence stage. At six- or twelve-month intervals, ask what happened to the milestones you underwrote.
Did deployment take longer than expected? Were customer references predictive of actual usage? Did the company need more capital to reach the same test? Were the strongest signals available before the cheque or only visible afterwards?
Do not equate a financing round with investment success. Early reviews can improve process, but financial returns remain unresolved until distributions and remaining value can be assessed properly.
Keep a sample of passed opportunities in the review too. Otherwise, the process teaches only from companies you chose. A pre-seed strategy becomes more repeatable when each cohort improves the questions, costs and evidence requirements applied to the next.
FAQ
What is pre-seed investing?
It funds a company's early development, often before repeatable commercial evidence exists. The label is used inconsistently. Define the evidence available and the next test being financed, whether that is a prototype, technical validation or proof that unrelated customers will pay.
Do you need a fund to invest at pre-seed?
No. Personal investments and suitably structured deal-by-deal arrangements are possible, as is a committed fund. The choice affects selection, funding certainty and administration. First-time managers are not universally barred from raising a fund; each route needs a coherent strategy and operating plan.
How should a pre-seed investor decide on follow-ons?
Reassess progress against the initial milestones, then underwrite the new security and price. Better company evidence does not automatically mean attractive new terms. Consider the remaining financing requirement and your total exposure before using reserves or trying to assemble fresh capital.
Can a pre-seed strategy be reviewed before exits happen?
Yes, through the quality of decisions and progress against documented milestones. Compare similar cohorts and retain passed opportunities in the review. Early operational learning can improve the process, while financial returns remain unresolved; a new funding round is not equivalent to a realised gain.
